Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Phase 3 PANTHER (Pevonedistat-3001) study did not achieve pre-defined statistical significance for the primary endpoint of event-free survival (EFS). The trial evaluated whether the combination of pevonedistat plus azacitidine as first-line treatment for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low-blast acute myeloid leukemia (AML) improved EFS versus azacitidine alone. An event in the trial is defined as death or transformation to AML in participants with higher-risk MDS or CMML, whichever occurs first, and death in participants with AML.
“While we are disappointed with this outcome, we are continuing to gain a greater understanding of the full data set and hope that findings from this Phase 3 study will provide information to help guide research and development for potential treatment options for these underserved patient populations,” said Chris Arendt, PhD, Head, Oncology Cell Therapy and Therapeutic Area Unit, Takeda. “We would like to thank the patients, families, advocacy organizations and investigators that participated in this trial, without whom this meaningful research would not have been possible. Takeda remains committed to conducting important research and transforming the lives of patients with cancer.”
Full data results will be submitted for presentation at an upcoming medical congress. Investigators have been informed of the outcome so they can discuss the potential impact with study participants. Takeda will work with investigators who will determine the most appropriate action for each individual patient enrolled in the study.
Pevonedistat is a NEDD8-activating enzyme (NAE) inhibitor that leads to cancer cell death by disrupting protein homeostasis. The Phase 3 PANTHER study (Pevonedistat-3001) did not achieve pre-defined statistical significance for the primary endpoint of event-free survival (EFS) and the data results are currently being evaluated. The safety profile was consistent with previously reported data for this combination. Pevonedistat is an investigational drug for which safety and efficacy have not been established.
Takeda’s Commitment to Oncology
Our core R&D mission is to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. Whether it’s with our hematology therapies, our robust pipeline, or solid tumor medicines, we aim to stay both innovative and competitive to bring patients the treatments they need. For more information, visit www.takedaoncology.com.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
+81 (0) 3-3278-3414
Media Outside Japan
+1 (617) 551-3683
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Square Launches Integrated, Omnichannel Solutions For Businesses in France21.9.2021 09:00:00 CEST | Press release
Today Square, the globally trusted software, payments, and hardware solution for businesses of all sizes, launches in France. Following a successful Early Access Programme, now small businesses and large enterprises across France can access Square’s innovative ecosystem with the tools they need to start, run, grow, and adapt their businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005137/en/ Square Launches Integrated, Omnichannel Solutions For Businesses in France (Photo: Business Wire) “I’ve been using Square’s products both on-site and online over the past few months and it has revolutionised how I run my business,” said Anne-Laure Fonrose, Founder of Tatie Nanna. “Having an integrated, omnichannel payment solution means our customers can pay in any way that suits them. It’s all been easy to set-up and run, the product looks great on site, and the connectivity is super-fast which helps avoid long queues. I’m
RedIRIS taps ADVA and SIA to upgrade national research network21.9.2021 09:00:00 CEST | Press release
ADVA (FSE: ADV) and SIA, Indra’s cybersecurity company, today announced that RedIRIS is deploying ADVA’s technology to create a robust, high-capacity research and education network (NREN). The new long-haul backbone infrastructure connects universities and research facilities across Spain, enabling educators and scientists to share huge data sets and harness bandwidth-intensive applications. Built on the ADVA FSP 3000 and monitored by the ADVA ALM fiber assurance solution, the network carries services at speeds up to 200Gbit/s. Featuring ADVA’s ROADM technology and QuadFlex™ line cards, the open solution has given RedIRIS an easy way to migrate from legacy technology to flexible, high-performance connectivity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005058/en/ ADVA is helping RedIRIS create a long-haul research and education network that stretches throughout Spain (Photo: Business Wire) “Our new transport system
Turquoise Plato Connects to OpenFin to Simplify Complexity on the Buy-Side Trader Desktop21.9.2021 09:00:00 CEST | Press release
OpenFin, the operating system (OS) for enterprise productivity, today announced that LSEG’s (London Stock Exchange Group) Turquoise Plato is connecting to OpenFin in response to the industry need for workflow efficiencies, application interoperability, and a more unified desktop experience for the buy-side and member firm users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005467/en/ Turquoise has a proven track record in delivering innovation and liquidity opportunities to the market, with Turquoise Plato Block Discovery™ having seen record levels of block trading activity on Turquoise® and Turquoise Europe™ in 2020. With this collaboration, Turquoise is continuing to deliver on its mission to identify efficient, collaborative operating models that reduce the implicit cost of trading, contribute to long-term investment returns and drive sustainable growth. Turquoise on OpenFin™ delivers an insightful data feed direc
Total Telecom: LG U+ Leads South Korea 5G Mobile Network Performance21.9.2021 08:30:00 CEST | Press release
Total Telecom features a new Umlaut 2021 audit report, which found that LG U+ outperforms KT and SKT Telecom (SKT) in Seoul, and achieved the highest Umlaut score despite owning significantly less amount of spectrum when compared with its rivals. It is the first time that Umlaut analysed mobile networks in South Korea regarding 5G mobile network performance. Umlaut scored networks under test basis data and voice quality. In Seoul, LG U+ took the leading place with a total score of 979 out of 1000, followed by KT and SKT, which have achieved total scores of 971 and 952 respectively. Like what the report has stated, LG U+ is equipped with the spectrum at 50MHz LTE, which is in lower frequency when compared to 55MHz for KT and 75MHz for SKT. Same situation also applies to the 5G New Radio (NR) spectrum, in which LG U+ is with 80 MHz, but both KT and SKT are with 100MHz. Despite equipping the spectrum with a lower frequency, LG U+ has the best performance in 5G user experience and 5G avail
Spotify Uses ReadSpeaker to Power Custom Voices for Car Thing Smart Player21.9.2021 08:00:00 CEST | Press release
ReadSpeaker, the most trusted, independent digital voice partner for global businesses, today announced that Spotify uses ReadSpeaker’s text-to-speech (TTS) technology to deliver custom voices for Spotify’s newest exploration in the US - a limited release of Car Thing, a smart player for your car. ReadSpeaker’s technology currently powers the custom voice available in Car Thing. Similar to the way the business world evolved from relying on websites to mobile apps as smartphones became popular, as the world moves beyond touchscreens and into a touchless future, consumers will become increasingly reliant on voice commands. ReadSpeaker believes that all brands have their own independent voice assistant, and custom voices will be critical in enabling brands to stand apart from competitors. Spotify uses ReadSpeaker’s technology and the ReadSpeaker VoiceLab because of the company’s deep expertise in custom branded voices powered by deep neural networks. Further, ReadSpeaker’s embedded and cl
Chase Arrives in the U.K. to Offer Consumers a Simple, Rewarding Banking Experience21.9.2021 07:00:00 CEST | Press release
JPMorgan Chase today launched its new digital bank in the U.K. under the Chase brand. Chase is the largest consumer bank in the United States and provides a broad range of financial services to more than 60 million American households. New customers can sign up at chase.co.uk, after which they will be invited to download the Chase app. Customers can open a current account in minutes via the simple and intuitive app. The account offers a range of features to help people budget, manage money, spend and save. A U.K.-led customer support team will be a key part of the Chase banking experience. With just a few taps in the Chase app, customers will be connected to a specialist – 24 hours a day, 7 days a week. Sanoke Viswanathan, CEO of the bank, said: “We’re offering people in the U.K. the opportunity to experience Chase for the first time with a current account that’s based on simplicity, a fuss free rewards programme and exceptional customer service.” The Chase current account will launch
dLocal Launches Direct Issuing, White-Labeled Prepaid Cards, in Emerging Markets21.9.2021 07:00:00 CEST | Press release
dLocal (NASDAQ:DLO), a technology-first payments platform enabling global enterprise merchants to connect with billions of consumers in emerging markets, announces the launch of dLocal’s Direct Issuing, a service enabling merchants to issue their own branded prepaid cardsfor online and in-store shopping in local currencies. Chilean fintech, Vita Wallet, is among the first to embrace the latest dLocal product. “Our Vita Card product aims to give our clients the best possible customer experience. With our cards - issued in partnership with dLocal - people will be able to shop, pay their bills, cash out, or even make and receive international payments much faster and cheaper than they would through banks,” says Moisés Zambrano, CBO, and Founder of Vita Wallet. Vita Wallet can instantly credit funds in local currencies, re-issue prepaid cards when expired, or block them when lost or stolen. Users can access their funds straight away. “Direct Issuing is part of our One dLocal integration. T
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom